Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals R&D

Sinovac Partners with Colombia University to Boost Vaccine R&D

Fineline Cube Oct 24, 2022

China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...

Company Deals

SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices

Fineline Cube Oct 24, 2022

Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...

Company Drug

MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8

Fineline Cube Oct 24, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...

Company Drug

Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma

Fineline Cube Oct 24, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...

Company Drug

Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications

Fineline Cube Oct 24, 2022

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...

Company Drug

AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial

Fineline Cube Oct 24, 2022

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...

Company Deals

Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M

Fineline Cube Oct 24, 2022

China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Fineline Cube Oct 24, 2022

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...

Company

Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce

Fineline Cube Oct 21, 2022

US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...

Drug R&D

Sinopharm’s Wuhan Institute Isolates Monkeypox Strains, Begins Vaccine Research

Fineline Cube Oct 21, 2022

China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...

Company Deals

CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization

Fineline Cube Oct 21, 2022

China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...

Policy / Regulatory

Fujian Procurement Center Announces VBP for Cardiac and Laparoscopic Medical Consumables

Fineline Cube Oct 21, 2022

The Fujian drug and device joint procurement center has released two separate notifications regarding the...

Policy / Regulatory

NMPA Releases 61st Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has released the 61st batch of reference drugs for...

Company Drug

Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA

Fineline Cube Oct 21, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...

Company Drug

Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid

Fineline Cube Oct 21, 2022

Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...

Company Drug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

Fineline Cube Oct 21, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...

Company Drug

China Approves GSK’s Juluca for HIV-1 Infection

Fineline Cube Oct 21, 2022

The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...

Company Drug

Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer

Fineline Cube Oct 21, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...

Company Deals

HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments

Fineline Cube Oct 20, 2022

China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...

Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Fineline Cube Oct 20, 2022

With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...

Posts pagination

1 … 613 614 615 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.